Deficiency of complement-dependent prevention of immune precipitation in systemic sclerosis

被引:14
作者
Arason, GJ [1 ]
Geirsson, AJ
Kolka, R
Víkingsdottir, T
Valdimarsson, H
机构
[1] Landspitali Univ Hosp Hringbraut, Dept Immunol, IS-101 Reykjavik, Iceland
[2] Landspitali Univ Hosp, Dept Med, IS-101 Reykjavik, Iceland
关键词
D O I
10.1136/ard.61.3.257
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Previous studies have indicated that complement may be activated or inherently abnormal in systemic sclerosis (SSc), and it has been suggested that immune complex deposition plays a part in the microvascular damage of this disease. Objective: To study several aspects of the complement system in 24 patients with SSc. Methods: Complement dependent prevention of immune precipitation (PIP) was measured by a sensitive enzyme immunoassay, levels of C1q, C4, and C3 by rocket immunoelectrophoresis, C4 allotypes by high voltage agarose electrophoresis, and C4A, C4B, and Cad by an enzyme linked immunosorbent assay (ELISA). Results: PIP was markedly decreased in the patients with SSc (p<0.001). Abnormal complement activation was detected in nine patients as raised levels of the complement split product Cad. However, a relation between low PIP and complement activation was not seen. PIP was significantly lower in patients who carried the C4A*Q0 allotype (p=0.03), and a strong correlation was found between PIP and C4A concentration (p<0.00001). The PIP defect may, at least in some patients, be associated with the initial phase of the disease. Conclusions: The results show a previously unrecognised functional defect of complement in SSc; the defect correlates with low levels of classical pathway components and, in particular, C4A.
引用
收藏
页码:257 / 260
页数:4
相关论文
共 16 条
[1]   Enzyme immunoassays for measuring complement-dependent prevention of immune precipitation (PIP) and solubilization of preformed antigen-antibody complexes (SOL) [J].
Arason, GJ ;
D'Ambrogio, MS ;
Víkingsdóttir, T ;
Sigfússon, A ;
Valdimarsson, H .
JOURNAL OF IMMUNOLOGICAL METHODS, 1999, 223 (01) :37-46
[2]   A MOLECULAR AND SEROLOGIC ANALYSIS OF THE MAJOR HISTOCOMPATIBILITY COMPLEX AND COMPLEMENT COMPONENT-C4 IN SYSTEMIC-SCLEROSIS [J].
BRIGGS, D ;
STEPHENS, C ;
VAUGHAN, R ;
WELSH, K ;
BLACK, C .
ARTHRITIS AND RHEUMATISM, 1993, 36 (07) :943-957
[3]   A COMPARISON OF THE PROPERTIES OF 2 CLASSES, C4A AND C4B, OF THE HUMAN-COMPLEMENT COMPONENT C-4 [J].
LAW, SKA ;
DODDS, AW ;
PORTER, RR .
EMBO JOURNAL, 1984, 3 (08) :1819-1823
[4]  
MCCOY RC, 1976, LAB INVEST, V35, P124
[5]   QUANTITATION OF THE HUMAN COMPONENT C4 - DEFINITION OF C4-Q0 ALLELES AND C4A DUPLICATIONS [J].
REBMANN, V ;
DOXIADIS, I ;
KUBENS, BS ;
GROSSEWILDE, H .
VOX SANGUINIS, 1992, 62 (02) :117-123
[6]  
SCHIFFERLI JA, 1982, CLIN EXP IMMUNOL, V47, P555
[7]  
Schneider P.M., 1997, COMPLEMENT PRACTICAL, P165
[8]   IMMUNE-COMPLEXES IN PROGRESSIVE SYSTEMIC-SCLEROSIS (SCLERODERMA) [J].
SEIBOLD, JR ;
MEDSGER, TA ;
WINKELSTEIN, A ;
KELLY, RH ;
RODNAN, GP .
ARTHRITIS AND RHEUMATISM, 1982, 25 (10) :1167-1173
[9]   ACTIVATION OF THE COMPLEMENT-SYSTEM IN SYSTEMIC-SCLEROSIS - RELATIONSHIP TO CLINICAL SEVERITY [J].
SENALDI, G ;
LUPOLI, S ;
VERGANI, D ;
BLACK, CM .
ARTHRITIS AND RHEUMATISM, 1989, 32 (10) :1262-1267
[10]  
Sullivan Kathleen E., 1998, Current Opinion in Pediatrics, V10, P600